Using chloroform as a preservative for trivalent foot and mouth disease vaccine in comparison to thiomersal | ||||
| المجلة العربية للعلوم الزراعية | ||||
| Article 4, Volume 2, Issue 3, 2019, Page 61-78 PDF (1.33 MB) | ||||
| Document Type: المقالة الأصلية | ||||
| DOI: 10.21608/asajs.2019.42725 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Assem A Mohamed; Wael Mosad; Mohamed A Gamil; Ehbal M Farouk; Amr I Hassanin; Hiam M Fakhry | ||||
| Department of FMD, Veterinary Serum and Vaccine Research Institute (VSVRI),Abassia, Cairo, Egypt | ||||
| Abstract | ||||
| Background: Chloroform has a potential value as a substitute for thiomersal as a preservative due to its high antibacterial and antifungal activity. Objective: Comparative analysis of the preservative efficacy of chloroform and thiomersal in ISA206 trivalent foot and mouth disease vaccine concerning the antimicrobial activity and vaccine potency. Method: This study was conducted on 5 prepared ISA206 trivalent foot and mouth disease vaccines, one vaccine prepared with 0.01% v/v thiomersal and four vaccines prepared with different concentrations of chloroform 0.1%,0.25%,0.5% and 0.75% v/v. Each vaccine was monthly evaluated by safety and sterility tests for 12 months. Three cattle were vaccinated intramuscularly (I/M) by each vaccine. Serum samples were collected monthly for 12 months.The humeral immune responses were monitored by Serum Neutralization Test (SNT) and Enzyme Linked Immunosorbent Assay (ELISA).The antimicrobial activity of chloroform and thiomersal in the five vaccines were determined 12 months post preparation against nine different gram negative and gram positive bacterial strains and three fungal stains. The bacterial strains were Bacillus subtilis, Staphylococcus aureus , Micrococcus luteus, Pseudo-monas aeruginosa, Escherichia coli, Salmonella typhi, Shig-ella flexneri, Salmonella para typhi A and Proteus mirabilis and fungal strains were Aspergillus flavus, Aspergillus nigar and Aspergillus pterus. Agar well diffusion method was followed in this study. The 12 monthes comparative analysis of antibacterial activity reflects that among these five vaccines. shows thiomersal as well Results: Our results show that the incorporation of as 0.5% and 0.75% chloroform into ISA206/FMDV vaccine are as effective as thiomersal as a preservative. Conclusion: Finally we recommended using 0.5% chloroform as a substitute for thiomersal as a preservative in foot and mouth disease vaccine. | ||||
| Keywords | ||||
| FMD Vaccine; chloroform; thiomersal; preservative | ||||
| References | ||||
|
Abdel- Rahman, A. O.; Farag, M. A.; Samira El- Kilany; Eman, M. A.; Manal Abo El- Yazed and Zeidan, S. (2006): Isolation and Identification of FMDV during an outbreak of 2006 in Egypt. Kafr El- Sheikh Vet. Med. J.; 4(1): 2006. Ahmed, H.A., S.A.H. Salem, A.R. Habashi, A.A. Arafa and M.G.A. Aggour et al., 2012. Emergence of foot-and-mouth disease virus SAT 2 in Egypt during 2012. Transboundary Emerg. Dis., 59: 476-481 Allende, A.J. Mende da silva ,G,Comparsie (2003) : South American standards for foot and mouth disease vaccine quality . Scientifiques et medicaies Els evier SAS. 331 -336 . Ayyappan, S.R., R. Srikumar and R. Thangaraj (2010): International Journal of Microbiology Research, 1(2), 67-71 Barnett, P.V, Pullen, L., Statham, R. and Salt J.(1996): Preliminary studies on ‘emergency’ foot-and-mouth disease vaccines formulated with metabolizable or semi- metabolizable oil adjuvants. Report, Session Group of the Standing Technical Committee of the European Commission For The Control of Foot-and-Mouth Disease and the Foot-and-Mouth Disease Subgroup of the Scientific Veterinary Committee of the Commission of the European Community, Israel, 1996. Belsham, G.J. (1993): Distinctive features of FMDV, a member of the Picorna virus family, aspects of virus protein synthesis, protein processing and structure. Progress in Biophysics and Molecular Biology 60: 241-260. Code of Federal regulation of USA (1986) : Published by the office of the federal register national archives and Record administration , Animal and animal products 9 / 1986. Committee of official Laboratories and Drug Control Services (1980): Third joint report of the Committee of Official Laboratories and Drug Control Services and the Section of Industrial Pharmacists-FIP (1980) The test for the eflectiveness of antimicrobial preservation of pharmaceuticals. fhummaceutica Acta Helvetiae,55.4049. El-Shehawy, L.I., H.I. Abu-Elnaga, S.A. Rizk, A.S. Abd El-Kreem, A.A. Mohamed and H.G. Fawzy, (2014) : Molecular differentiation and phylogenetic analysis of the Egyptian foot-and-mouth disease virus SAT2. Arch. Virol., 159: 437-443. FAO (2012). Foot-and-mouth disease caused by serotype SAT2 in Egypt and Libya. Empres watch, Vol. 25 – March 2012. Farag, M.A., Aggour, M. A. and Daoud, A.M. (2005): ELISA as a rapid method for detecting the correlation between the field isolates of FMD and the current used vaccine strain in Egypt. Vet. Med. J. Giza, Vol. 53 no. 4: 949- 955. Gatsing, D., D.,J. A. Mbah, I. H. Garba, P. Tane, P. Djemgou and B. F. Nji-Nkah (2006) : “An Antisalmonellal Agent from the Leaves of Glossocalys. Brevipes Benth (Monimiaceae),” Pakistan Journal of Biological Sciences, Vol. 9, No. 1, 2006, pp. 84-87. Ghoneim, N.H., Abdel-Karim, A.K.M., El-Shehawy, L., Abdel-Moein, K.A. 2010. Foot and Mouth Disease in Animals in Sharkia Governorate – Egypt. Transbound. Emerg. Dis. 57: 19-21. Hamblin C, Barnett I T R and Crowther J R (1986): Anew Enzyme-Linked Immuno Sorbent Assay (ELISA) for the detection of antibodies against FMD virus. П Application. Journal of immunological methods, 93: 123-129. Hema, T.A., A.S. Arya, Subha Suseelan, R.K. John Cesestinal and P.V. Divya (2013): Int. J. Pharm. Bio. Sci., 4(1), 70-80. Josephin Sheeba, B. and T. Selva Mohan (2012): Asian J. Plant Sci. Res., 2(2), 83-88. Kallings. L.O., Ringertz, O., Silverstolpe. L.& Ernerfeldt, F.( 1966): Microbiological contamination of medical products. Acta fharrnaceutica Suecica. 3.7 19-228. Kandeil, A., R. El-Shesheny, G. Kayali, Y. Moatasim and O. Bagato (2013) : Characterization of the recent outbreak of foot-and-mouth disease virus serotype SAT2 in Egypt. Arch. Virol., 158: 619-627. Karber. G (1931):Beitrage Zurich kille kiven behand-lung pharmakologis reihenver-suche nanny shied berg.Arch.Exp.Path.pharmak; 126:280-283. Knowles, N.J., J. Wadsworth, S.M. Reid, K.G. Swabey and A.A. El-Kholy ( 2007) : Foot-and-mouth disease virus serotype A in Egypt. Emerg. Infect. Dis., 13: 1593-1596. Lynch, M.. Lund,V. & Wilson, D.A. (1977): Chloroform as a preservative in aqueous systems. Phurmaceuti-ral Journal, 219,507-5 10. Martindale (2007): The Complete Drug Reference, Sweetman S.C. Ed., 35th edn., pharmaceutical Press, London 2007. Mousa,A.A.;Boulaus,S.M.;Elsayed;,F.S.andBohm,H.O.(1974): Typing and subtyping of a strain of FMD isolated from sharquia province, 1970.J.egypt,assuit Veterinary Medicine, Vol.(34) No.(3-4) : (413-419). Nair,S.P. and Sen,A.K. (1992): “A comparative study on the immune response of sheep to FMD virus vaccine type Asia1 prepared with different inactivators and adjuvants”. Comp. Immunol. Microbiol. Infect. Dis., 15(2): 117-124. Nweze, E. T., J. I. Okafor and O.J. Njoku (2004): Bio. Res. Biotechnol., 2(1), 34. Orsel,K.;deJong,M.C.;Bouma,A.;Stegeman,J.A.andDekker,A.(2007): Foot and mouth disease virus transmission among vaccinated pigs after exposure to virus shedding pigs. Vaccine2 21;25(34):6381-91. OIE(2000) : OIE manual of standards : Anon. Section 2.1. List - Diseases, Chapter 2.1.1. Foot-and-mouth disease. OIE manual of standards for diagnostic tests and vaccines; 4th Ed. 2000, Paris,77-92 OIE (2009) : Terrestrial Manual 2009 (5), Foot and mouth disease (Chapter 2.1.5.) (1-29). Parekh, J., D. Jadeja and S. Chanda (2005) :Turkish Journal of Biology, 29, 203-210. Pharmaceutical Society Working Party (1971): Microbial contamination in harmaceuticals for oral and topical use: report of the Pharmaceutical Society’s working party. hannaceuiical Jorrrnal, 207,400-402. Public Health Laboratory Service Working Party (1971): Microbial contamination of medicines adminis-tered to hospital patients: report of the Public Health Laboratory Service working party. Fhurmaceutical Journal, 207,9699. Rajakaruna, N., C.S. Harris and G.H.N. Towers (2002). Pharmaceutical Biology, 40, 235-244. Reddy, G.S.; K.Ananda Rao and VA Srinivasan (2001 ): Performance of oil adjuvant combined vaccine containing FMD, rabies, Pasteurella multocida and Clostridium chauvoei antigens . Indian veterinary journal · November 2001 : 78: 990 993 Rybacki E., Stozek T.(1980):Excipients in the tech-nology of drug forms (Polish), Biblioteka far-maceuty Vol. 7, PZWL, Warszawa 1980. Shastri R. V. and Varudkar, J. S (2009) :Synthesis and Antim-icrobial Activity of 3-Propen-1,2-benzisoxazole Deriva-tives,” Indian Journal of Chemical Sciences, Vol. 48B, 2009, pp. 1156-1160. Shawky M., Abd El-Aty M., Hiam. M. Fakry, Hind M. Daoud, Ehab El-Sayed I., Wael Mossad G., Sonia A. Rizk, Abu-Elnaga H., Mohamed A. A., Abd El-kreem A. and Farouk E. M. (2013) : Isolation and Molecular Characterization of Foot and Mouth Disease SAT2 Virus during Outbreak 2012 in Egypt . J Vet Adv 2013, 3(2): 60-68 Thc Pharmaceutical Codex (1979): I Ith edition. pp. 175 and xvi. The Pharmaceutical Press, London. Vedhanarayanan, P., T. Vaithiyanathan and P. Sundaramoorthy (2015) : Antimicrobial activity of chloroform and methanol extract of lennea coromandelica merr. International Letters of Natural Sciences Online: 2015-08-28 ISSN: 2300-9675, Vol. 45, pp 67-74. Vinoth, B. and R. Manivasagaperumal (2015): Int. J. Pharm. Bio. Sci., 6(2), 613-620. Zahran, G.E.D. (1960): Foot and mouth disease in southern region of URA.Bull. Off. Int. Epiz., 13: 390- 393. | ||||
|
Statistics Article View: 406 PDF Download: 236 |
||||
